- Earlier this month, Capricor Therapeutics reported Q4 2025 and full-year results showing a wider net loss of US$30.17 million for the quarter and US$105.04 million for the year, alongside continued investment in its Duchenne muscular dystrophy pipeline.
- A key development was new Phase 3 HOPE-3 data and the FDA’s decision to resume review of Deramiocel’s Biologics License Application, setting an August 22, 2026 action date for a potential decision on treating Duchenne cardiomyopathy.
- With the FDA review back on track and stronger HOPE-3 functional data presented, we’ll examine how this reshapes Capricor’s investment narrative.
We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Capricor Therapeutics Investment Narrative Recap
To own Capricor today, you need to believe Deramiocel can convert its Duchenne data and regulatory designations into a first commercial product before cash burn and competition bite too hard. The FDA’s decision to resume BLA review and set an August 22, 2026 action date is now the key short term catalyst, while the widening US$105.04 million annual net loss keeps funding needs and dilution risk firmly in focus.
The most relevant update is the FDA lifting its prior Complete Response Letter and restarting review of Deramiocel’s BLA as a Class 2 resubmission. Paired with the strengthened HOPE 3 functional and cardiac data, this gives clearer sightlines on the timing and evidentiary basis of the approval decision that underpins Capricor’s story, even as the company remains pre revenue and loss making.
Yet against this progress, investors should also be aware that...
Read the full narrative on Capricor Therapeutics (it's free!)
Capricor Therapeutics' narrative projects $134.4 million revenue and $14.4 million earnings by 2028. This requires 115.7% yearly revenue growth and an $84.4 million earnings increase from $-70.0 million today.
Uncover how Capricor Therapeutics' forecasts yield a $50.80 fair value, a 64% upside to its current price.
Exploring Other Perspectives
Before this news, the most cautious analysts assumed years of losses with zero product revenue and only about US$68.3 million of sales by 2028, so if you are weighing HOPE 3 against the risk of prolonged approval delays and dilution, it is worth comparing this more pessimistic view with your own expectations.
Explore 7 other fair value estimates on Capricor Therapeutics - why the stock might be worth over 10x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Capricor Therapeutics research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Capricor Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Capricor Therapeutics' overall financial health at a glance.
Searching For A Fresh Perspective?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com